Literature DB >> 6765958

Magnitude of the fetal hemoglobin response to acute hemolytic anemia in baboons is controlled by genetic factors.

J DeSimone, P Heller, J Amsel, M Usman.   

Abstract

When hemolytic anemia was induced in 26 baboons (Papio cynocephalus), aged 7-22 mo, they increased their production of fetal hemoglobin (HbF). Although the resulting reduction in hematocrits and increases of reticulocyte counts were similar in all stressed animals there was marked variability in the maximal rates of HbF synthesis. The maximal levels of HbF attained appeared to fall into three separate groups: low, intermediate, and high. These differences were not related to sex or several measures of erythrocyte metabolism. Animals exposed to repeated episodes of erythropoietic stress after full hematologic recovery demonstrated some variability in their maximal HbF levels attained from one episode to another, but these variations never extended to adjacent classes. The described biochemical and mating data suggest that the magnitude of the HbF response to hemolytic anemia is controlled by genetic factors.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6765958      PMCID: PMC371358          DOI: 10.1172/JCI109654

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  4 in total

1.  Hemopoietic stress and fetal hemoglobin synthesis: comparative studies in vivo and in vitro.

Authors:  J DeSimone; P Heller; J G Adams
Journal:  Blood       Date:  1979-11       Impact factor: 22.113

2.  Genetic control of F cells in human adults.

Authors:  M A Zago; W G Wood; J B Clegg; D J Weatherall; M O'Sullivan; H Gunson
Journal:  Blood       Date:  1979-05       Impact factor: 22.113

3.  Fetal haemoglobin production and the sickle gene in the oases of Eastern Saudi Arabia.

Authors:  M E Pembrey; W G Wood; D J Weatherall; R P Perrine
Journal:  Br J Haematol       Date:  1978-11       Impact factor: 6.998

4.  Stimulation of fetal hemoglobin synthesis in baboons by hemolysis and hypoxia.

Authors:  J DeSimone; S I Biel; P Heller
Journal:  Proc Natl Acad Sci U S A       Date:  1978-06       Impact factor: 11.205

  4 in total
  7 in total

Review 1.  Fetal Hemoglobin Induction by Epigenetic Drugs.

Authors:  Donald Lavelle; James Douglas Engel; Yogen Saunthararajah
Journal:  Semin Hematol       Date:  2018-04-22       Impact factor: 3.851

Review 2.  Developmental genetics of the human haemoglobins.

Authors:  W G Wood; D J Weatherall
Journal:  Biochem J       Date:  1983-10-01       Impact factor: 3.857

3.  5-Azacytidine stimulates fetal hemoglobin synthesis in anemic baboons.

Authors:  J DeSimone; P Heller; L Hall; D Zwiers
Journal:  Proc Natl Acad Sci U S A       Date:  1982-07       Impact factor: 11.205

Review 4.  Epigenetic regulation of hemoglobin switching in non-human primates.

Authors:  Robert Molokie; Joseph DeSimone; Donald Lavelle
Journal:  Semin Hematol       Date:  2020-12-28       Impact factor: 3.851

5.  A Nonhuman Primate Transplantation Model to Evaluate Hematopoietic Stem Cell Gene Editing Strategies for β-Hemoglobinopathies.

Authors:  Olivier Humbert; Christopher W Peterson; Zachary K Norgaard; Stefan Radtke; Hans-Peter Kiem
Journal:  Mol Ther Methods Clin Dev       Date:  2017-11-21       Impact factor: 6.698

Review 6.  Targeting sickle cell disease root-cause pathophysiology with small molecules.

Authors:  Yogen Saunthararajah
Journal:  Haematologica       Date:  2019-08-08       Impact factor: 9.941

7.  Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: A randomized phase 1 study.

Authors:  Robert Molokie; Donald Lavelle; Michel Gowhari; Michael Pacini; Lani Krauz; Johara Hassan; Vinzon Ibanez; Maria A Ruiz; Kwok Peng Ng; Philip Woost; Tomas Radivoyevitch; Daisy Pacelli; Sherry Fada; Matthew Rump; Matthew Hsieh; John F Tisdale; James Jacobberger; Mitch Phelps; James Douglas Engel; Santhosh Saraf; Lewis L Hsu; Victor Gordeuk; Joseph DeSimone; Yogen Saunthararajah
Journal:  PLoS Med       Date:  2017-09-07       Impact factor: 11.069

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.